Zacks Research Has Pessimistic Outlook of CORT Q1 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for Corcept Therapeutics in a note issued to investors on Wednesday, December 18th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings per share of $0.27 for the quarter, down from their previous forecast of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.34 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.53 EPS, Q2 2026 earnings at $0.55 EPS, Q3 2026 earnings at $0.71 EPS and FY2026 earnings at $2.41 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. During the same quarter in the prior year, the firm earned $0.28 EPS. Corcept Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis.

Several other analysts have also recently commented on the company. Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Piper Sandler boosted their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 18th. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Finally, Truist Financial upped their target price on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics currently has a consensus rating of “Buy” and an average price target of $65.25.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $51.15 on Friday. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $62.22. The company has a 50-day moving average price of $53.71 and a 200 day moving average price of $41.78. The company has a market cap of $5.36 billion, a P/E ratio of 40.60 and a beta of 0.51. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. M&G PLC purchased a new stake in shares of Corcept Therapeutics during the third quarter worth about $11,173,000. Empowered Funds LLC acquired a new stake in Corcept Therapeutics during the third quarter worth approximately $1,784,000. Victory Capital Management Inc. grew its stake in Corcept Therapeutics by 49.2% in the 3rd quarter. Victory Capital Management Inc. now owns 41,823 shares of the biotechnology company’s stock worth $1,936,000 after acquiring an additional 13,787 shares during the period. State Street Corp raised its holdings in Corcept Therapeutics by 0.6% in the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock valued at $162,871,000 after acquiring an additional 19,893 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Corcept Therapeutics by 20.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 859,563 shares of the biotechnology company’s stock worth $39,781,000 after purchasing an additional 143,507 shares during the period. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Corcept Therapeutics

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.88, for a total value of $131,736.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Joseph Douglas Lyon sold 1,411 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.72, for a total value of $80,031.92. Following the sale, the insider now directly owns 8,494 shares in the company, valued at approximately $481,779.68. The trade was a 14.25 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,811 shares of company stock valued at $1,341,360. Insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.